Exhibit 99.1 Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., February 12, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. The study did not meet its primary or key secondary endpoints. ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── The study demonstrated reductions from baseline in hypoglycemia events by self-monitored blood glucose at both ersodetug dose levels, but reductions were not statistically significant compared to placebo, due to a pronounced study effect. A reduction in hypoglycemia time by continuous glucose monitoring (C…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Rezolute, Inc.
RZLTNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.…
Press release in this filing
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update →Company context
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
Current securities
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On
February 12, 2026, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31,
2025. A copy of this press release is attached hereto as Exhibit 99.1.
The
information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current
Report on Form 8-K.